Label: DESONIDE lotion

  • NDC Code(s): 51672-4079-4, 51672-4079-8
  • Packager: Taro Pharmaceuticals U.S.A., Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 5, 2019

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    FOR EXTERNAL USE ONLY. FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE.

  • DESCRIPTION

    Desonide Lotion 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17[(1methylethylidene) bis(oxy)]-,(11β,16α)- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.

    Chemically, desonide is C24H32O6. It has the following structural formula:

    Chemical Structure

    Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water.

    Each gram of desonide lotion contains 0.5 mg of desonide in a base of cetyl alcohol, diethylene glycol monoethyl ether, edetate disodium, glyceryl stearate/polyethylene glycol, light mineral oil, methylparaben, purified water, propylene glycol, propylparaben, sodium lauryl sulfate, sorbitan monostearate and stearyl alcohol. Contains citric acid monohydrate and sodium hydroxide for pH adjustment.

  • CLINICAL PHARMACOLOGY

    Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

    Pharmacokinetics

    The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

    Studies performed with desonide lotion indicate that they are in the low to medium range of potency as compared with other topical corticosteroids.

  • INDICATIONS AND USAGE

    Desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

  • CONTRAINDICATIONS

    Desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

  • PRECAUTIONS

    General

    Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

    Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.

    If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

    Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS: Pediatric Use).

    If irritation develops, desonide lotion should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

    If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of desonide lotion should be discontinued until the infection has been adequately controlled.

    Information for Patients

    Patients using topical corticosteroids should receive the following information and instructions:

    1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
    2. This medication should not be used for any disorder other than that for which it was prescribed.
    3. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
    4. Patients should report to their physician any signs of local adverse reactions.

    Laboratory Tests

    The following tests may be helpful in evaluating patients for HPA axis suppression:

     
    ACTH stimulation test
     
    A.M. plasma cortisol test
     
    Urinary free cortisol test

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on reproduction with the use of desonide lotion.

    Pregnancy

    Teratogenic Effects

    Pregnancy Category C

    Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproduction studies have not been conducted with desonide lotion. It is also not known whether desonide lotion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Desonide lotion should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when desonide lotion is administered to a nursing woman.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

  • ADVERSE REACTIONS

    In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.

    The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.

  • OVERDOSAGE

    Topically applied desonide lotion can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

  • DOSAGE AND ADMINISTRATION

    Desonide lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition. SHAKE LOTION WELL BEFORE USING.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

    Desonide lotion should not be used with occlusive dressings.

  • HOW SUPPLIED

    Desonide Lotion, 0.05% is supplied as follows:

    2 fl oz (59 mL) bottle – NDC 51672-4079-4
    4 fl oz (118 mL) bottle – NDC 51672-4079-8

    Storage Conditions

    Store between 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

    SHAKE WELL BEFORE USING.

  • SPL UNCLASSIFIED SECTION

    Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761
    Distributed by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

    Revised: May, 2014
    70119-0514-3
    384

  • PRINCIPAL DISPLAY PANEL - 118 mL Bottle Carton

    118 mL

    Net Wt. 4 fl oz

    NDC 51672-4079-8

    Desonide
    Lotion
    0.05%

    FOR EXTERNAL USE ONLY.
    FOR DERMATOLOGIC
    USE ONLY.
    NOT FOR OPHTHALMIC USE.
    SHAKE WELL BEFORE USING.

    Keep this and all
    medications out of the
    reach of children.

    Rx only

    TARO

    PRINCIPAL DISPLAY PANEL - 118 mL Bottle Carton
  • INGREDIENTS AND APPEARANCE
    DESONIDE 
    desonide lotion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51672-4079
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Desonide (UNII: J280872D1O) (Desonide - UNII:J280872D1O) Desonide0.5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    cetyl alcohol (UNII: 936JST6JCN)  
    citric acid monohydrate (UNII: 2968PHW8QP)  
    diethylene glycol monoethyl ether (UNII: A1A1I8X02B)  
    edetate disodium (UNII: 7FLD91C86K)  
    light mineral oil (UNII: N6K5787QVP)  
    methylparaben (UNII: A2I8C7HI9T)  
    water (UNII: 059QF0KO0R)  
    propylene glycol (UNII: 6DC9Q167V3)  
    propylparaben (UNII: Z8IX2SC1OH)  
    sodium hydroxide (UNII: 55X04QC32I)  
    sodium lauryl sulfate (UNII: 368GB5141J)  
    sorbitan monostearate (UNII: NVZ4I0H58X)  
    stearyl alcohol (UNII: 2KR89I4H1Y)  
    Product Characteristics
    ColorWHITEScore    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51672-4079-41 in 1 CARTON10/31/2014
    159 mL in 1 BOTTLE; Type 0: Not a Combination Product
    2NDC:51672-4079-81 in 1 CARTON10/31/2014
    2118 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20216110/31/2014
    Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370)
    Establishment
    NameAddressID/FEIBusiness Operations
    Taro Pharmaceutical Industries Ltd.600072078ANALYSIS(51672-4079) , MANUFACTURE(51672-4079)